本帖最后由 老马 于 2013-3-13 13:43 编辑 ! T K) [% C8 K! a' [
% o, n L# @3 N) R' O
健择(吉西他滨)+顺铂+阿瓦斯汀
3 W% [' d/ ]2 o! D8 t) j. L) A Gemzar +Cisplatin + Avastin
) t$ @4 g+ U$ n! n2 A1 o+ Uhttp://annonc.oxfordjournals.org/content/21/9/1804.full8 M1 U+ L9 N1 n; R7 W6 i; f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! @( ^- B K" NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 z2 l( r M; ]+ H
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 6 I8 ?) K8 Y: C- j4 `8 e
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
/ G( s# u( o6 o* t% @华为网盘附件:
% G0 G" ^5 [$ S. t% P$ Z' t2 N0 z【华为网盘】ava.JPG/ [5 F5 O6 O V( o
|